Stabilized soluble glycoprotein trimers
View Patent ↗The present application is directed to stabilized HIV envelope glycoprotein trimers. The trimers are stabilized by introducing trimeric motifs, preferably the GCN4 coiled coil or the fibritin trimeric domain at certain sites, for example in the gp41 ectodomain. These stabilized trimers or DNA molecules encoding such trimers can be used to generate an immunogenic reaction. The trimers can also be used in assays to screen for molecules that interact with them—and to identify molecules that interact with specific sites.
1. A stable trimer of three HIV-1 or HIV-2 soluble envelope glycoprotein monomers, wherein each monomer contains a HIV-1 gp120 protein or HIV-2 gp125 protein, referred to as the gp120 protein, wherein at least one monomer is modified, wherein the modified monomer maintains the overall three-dimensional structure of the wildtype gp120 monomer, wherein a portion of one variable region of the modified monomer has been deleted and wherein a trimeric motif has been added carboxyl to the gp120 protein.
2. The stable trimer of claim 1 , wherein the modified monomer further comprises a linker inserted at a site corresponding to the natural cleavage site between the gp120 protein and the transmembrane protein (gp41), wherein the natural cleavage site has been disrupted.
3. The trimer of claim 1 , wherein each modified monomer does not contain amino acid residues corresponding to its transmembrane region and its gp120/gp41 cleavage site.
4. The trimer of claim 3 , wherein each modified monomer does not contain the transmembrane and cytoplasmic regions of gp41.
5. The trimer of claim 4 , wherein a disulphide bridge is introduced within the coiled coil structure.
6. The trimer of claim 3 or 4 , wherein the HIV-1 monomer is modified such that the monomer terminates at a site corresponding to amino acid residue Leu 593 of HIV-1 strain YU2, and wherein a cysteine pair and a glycine residue at the carboxy terminus end of the precursor have been added or substituted for other amino acid residues.
7. The trimer of claim 1 , wherein the monomer is modified such that the monomer terminates immediately N-terminal to the transmembrane region, and the natural cleavage site between gp120/gp41 of the precursor of the HIV-1 gp120 protein is not present.
8. The trimer of claim 7 , wherein a disulphide bridge is introduced within a coiled coil structure corresponding to the coiled coil structure of a HIV-1 gp41 protein.
9. The trimer of claim 7 or 8 , wherein a cysteine pair and a glycine residue at the carboxy terminal end of the precursor of the HIV-1 gp122 have been added or substituted for other amino acid residues.
10. The trimer of claim 1 , wherein the trimeric motif is the carboxy terminus of each monomer.
11. The trimer of claim 3 or 4 , wherein the trimeric motif is the carboxy terminus of each monomer.
12. The trimer of claim 7 or 8 , wherein the trimeric motif is the carboxy terminus of each monomer.
13. The trimer of claim 1 , wherein a trimeric motif is inserted N-terminal to a site corresponding to a transmembrane region in a precursor to the gp120 protein, and wherein said transmembrane region is deleted or substituted, and a site in the precursor to the gp120 protein corresponding to a natural cleavage site between its transmembrane protein and the gp120 protein has been disrupted.
14. The trimer of claim 13 , wherein the trimeric motif is a coiled coil.
15. The trimer of claim 14 , wherein the protein terminates after the coiled coil.
16. The trimer of claim 1 , wherein the trimeric motif is a GCN4 trimeric motif or a fibritin trimeric motif.
17. The trimer of claim 1 , wherein the trimeric motif is SEQ ID NO:1.
18. The protein of claim 1 , wherein the trimeric motif is SEQ ID NO:4.